Search research articles
Contact Us
Filters
Showing results (51-60 of 115) with videos related to
Page
of 12
Sort By:
Scandinavian Journal of Urology and Nephrology
|
June 1, 1996
Development of anti-OKT3 antibodies after OKT3 treatment
P B Jensen, S A Birkeland, N Rohrp, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 21, 2000
A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer
M Sorensen, P B Jensen, J Herrstedt, et al.
Mitochondrion
|
February 8, 2012
Microscale oxygraphy reveals OXPHOS impairment in MRC mutant cells
F Invernizzi, I D'Amato, P B Jensen, et al.
British Journal of Cancer
|
July 2, 1998
Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation
M Sorensen, M Sehested, I J Christensen, et al.
British Journal of Cancer
|
February 1, 1993
Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines
P B Jensen, I J Christensen, M Sehested, et al.
Cancer Communications
|
January 1, 1990
The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor
E Friche, P B Jensen, M Sehested, et al.
Investigational New Drugs
|
November 1, 1989
Reduced variation in the clonogenic assay obtained by standardization of the cell culture conditions prior to drug testing on human small cell lung cancer cell lines
P B Jensen, H Roed, L Vindeløv, et al.
British Journal of Cancer
|
July 1, 1990
Transport of the multidrug resistance modulators verapamil and azidopine in wild type and daunorubicin resistant Ehrlich ascites tumour cells
M Sehested, T Skovsgaard, P B Jensen, et al.
Maturitas
|
November 1, 1987
Climacteric symptoms after oral and percutaneous hormone replacement therapy
P B Jensen, J Jensen, B J Riis, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
June 1, 2000
Plasma Escherichia coli beta-galactosidase as a marker of tumor burden and response to experimental anti-neoplastic therapy in nude mice xenografted with lacZ transduced human tumor cells
C Holst-Hansen, R W Stephens, B E Johannessen, et al.
Page
of 12
Search research articles
Search
Showing results (51-60 of 115) with videos related to
Sort By:
Page
of 12
Scandinavian Journal of Urology and Nephrology
|
June 1, 1996
Development of anti-OKT3 antibodies after OKT3 treatment
P B Jensen, S A Birkeland, N Rohrp, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 21, 2000
A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancer
M Sorensen, P B Jensen, J Herrstedt, et al.
Mitochondrion
|
February 8, 2012
Microscale oxygraphy reveals OXPHOS impairment in MRC mutant cells
F Invernizzi, I D'Amato, P B Jensen, et al.
British Journal of Cancer
|
July 2, 1998
Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation
M Sorensen, M Sehested, I J Christensen, et al.
British Journal of Cancer
|
February 1, 1993
Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines
P B Jensen, I J Christensen, M Sehested, et al.
Cancer Communications
|
January 1, 1990
The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor
E Friche, P B Jensen, M Sehested, et al.
Investigational New Drugs
|
November 1, 1989
Reduced variation in the clonogenic assay obtained by standardization of the cell culture conditions prior to drug testing on human small cell lung cancer cell lines
P B Jensen, H Roed, L Vindeløv, et al.
British Journal of Cancer
|
July 1, 1990
Transport of the multidrug resistance modulators verapamil and azidopine in wild type and daunorubicin resistant Ehrlich ascites tumour cells
M Sehested, T Skovsgaard, P B Jensen, et al.
Maturitas
|
November 1, 1987
Climacteric symptoms after oral and percutaneous hormone replacement therapy
P B Jensen, J Jensen, B J Riis, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology
|
June 1, 2000
Plasma Escherichia coli beta-galactosidase as a marker of tumor burden and response to experimental anti-neoplastic therapy in nude mice xenografted with lacZ transduced human tumor cells
C Holst-Hansen, R W Stephens, B E Johannessen, et al.
Page
of 12